New research is being undertaken to determine whether paramedics can safely assess and manage patients with chest pain without them necessarily having to go to hospital, providing early reassurance as well as reducing stress on ambulance crews and A&E departments.
Oxford Genetics has won six new licensing deals for its scalable gene therapy manufacturing technologies.
NHS Improvement has appointed Prerana Issar as its new chief people officer.
Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).
Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years.
A late-stage study of Novavax’ respiratory syncytial virus vaccine ResVax has failed to hit its main goal.
Innovate UK and Asthma UK are joining forces to improve treatment for asthma.
Researchers have discovered a cell mechanism that repairs potentially cancerous DNA damage.
Novartis has teamed up with biopharmaceutical investor Blackstone Life Sciences to launch a new biotech start up, Anthos Therapeutics.
UK group Healx is to collaborate with Boston Children’s Hospital and Barth Syndrome Foundation for Barth syndrome.
The CMA has provisionally found that Auden Mckenzie and Waymademay entered into illegal anti-competitive agreements regarding the supply of hydrocortisone tablets.
Target PharmaSolutions has named Novartis as its first TARGET-DERM registry industry partner.
Bristol-Myers Squibb’s planned $74-billion purchase of Celgene has hit a significant obstacle after its largest institutional shareholder said it did not back the deal.
NHS patients are set to receive therapy to “counteract the impact of harmful social media” as part of a new service designed to treat the rare eating disorder diabulimia.
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
